An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

Study Identifier
019-05-06-CR
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Dyslipidemia
  • Study Drug
  • Niacin ER/Simvastatin Tablets
  • atorvastatin
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    21+ years

    Protocol Summary

    To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin

    (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating

    effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are

    currently off lipid-modifying therapy. This was a prospective, randomized, open-label,

    blinded endpoint (PROBE) study.

    Study Locations

    Location
    Status
    Location
    Anaheim, California, United States, 92801
    Status
    Not applicable
    Location
    Huntington Park, California, United States, 90255
    Status
    Not applicable
    Location
    Long Beach, California, United States, 90822
    Status
    Not applicable
    Location
    Sacramento, California, United States, 95825
    Status
    Not applicable
    Location
    Walnut Creek, California, United States, 94598
    Status
    Not applicable
    Location
    Brooksville, Florida, United States, 34613
    Status
    Not applicable
    Showing {first} - {last} of {total} Results